Rhône-Poulenc Forms Network To Develop Gene and Cell Therapies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France) has formed a new division, RPR Gencell, dedicated to the discovery, development, and commercialization of cell and gene therapy products. To accelerate such discoveries, the company has also created a biotechnology network comprising 14 biotech companies and academic research centers.

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France)has formed a new division, RPR Gencell, dedicated to the discovery,development, and commercialization of cell and gene therapy products.To accelerate such discoveries, the company has also created abiotechnology network comprising 14 biotech companies and academicresearch centers.

The US members of the collaboration are Genetix Pharmaceuticals(New York City), The Lawrence Berkeley Laboratory Human GenomeCenter (Berkeley, Calif), Applied Immune Sciences, Inc. (SantaClara, Calif), Darwin Molecular Corporation (Seattle), and IntrogenTherapeutics, Inc. (Houston).

The other network members are French, including the Centre Nationalde Recherche Scientifique (CNRS), the Institut Gustave Roussy,and the Université Louis Pasteur.

Articles in this issue
MDs Fear Managed Care Equals Lower-Quality Care
Dallas Medical Center Launches Umbilical Stem Cell Project
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
European Trials Show Dose-Related Efficacy of Docetaxel In Metastatic Breast Cancer, Value of Steroid Pretreatment
Ethyol Approved for Use in the UK
Success of Breast Conserving Surgery Is Not Diminished in Community Setting
Assessment Tools Are Essential to Improve Management of Pain
Undertreating Pain Costs Money in the Long Run, Physician Warns
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
EORTC Endometrial Ca Trial Challenges Findings From GOG
Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small
Antibiotic Regimen Leads to Lymphoma Regression
Look for Incremental Insurance Reform Steps With New Congress
Court Upholds Patents on AZT
Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content
Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.

New Legislation May Help Reduce Extravasation Rates in Cancer Radiology

Roman Fabbricatore
April 23rd 2025
Article

Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Roman Fabbricatore
April 23rd 2025
Article

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

BOLDSCIENCE;Pedram Razavi;Judith Balmaña;Stephen Luen;Mario Campone;Laura Cortesi;Norikazu Masuda;Kyong Hwa Park;Qingyuan Zhang;Emily Nizialek;Cathy Qi;Karen Cui;Sibylle Loibl;Mark Robson, MD;Filipa Lynce
April 22nd 2025
Article
"These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions," according to Keiji Inoue, MD, PhD, a professor in the Department of Urology at Kochi Medical School.

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

Russ Conroy
April 22nd 2025
Article

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.